Dossier review provides the documentary basis for judging whether a pharmaceutical product aligns with internationally recognized standards. It is considered together with manufacturing-site evaluation, sample testing, and clinical evidence rather than treated as an isolated step. This combined assessment helps create a more complete picture of product reliability for procurement and public health decisions.
Manufacturing-site evaluation examines the setting in which a product is produced and supports assessment of whether manufacturing standards are applied consistently. This matters because reliable supply depends not only on the product itself but also on the processes used to make it. The resulting information can strengthen confidence in medicines selected for national programs and global health initiatives.
Testing product samples adds an assessment based on the medicine itself to the documentary and site-based parts of the process. When combined with dossier review and manufacturing evaluation, sample testing helps support a broader judgment about quality. This evidence is useful when agencies and programs need greater confidence in products entering public-sector procurement channels.
Clinical evidence addresses whether a medicine has an appropriate basis for evaluating safety and efficacy, two central considerations in clinical practice. Its review complements quality-focused activities such as dossier assessment, site evaluation, and sample testing. Together, these elements help public health programs select treatments with evidence supporting their intended clinical use.
Continued monitoring extends oversight beyond the initial assessment and recognizes that confidence in a medicine must be maintained over time. It provides a way to keep attention on product quality, safety, and efficacy after approval. For procurement agencies and national programs, ongoing monitoring supports more dependable medicine supply and sustained public health confidence.
Procurement agencies and national programs can use prequalification findings when selecting medicines, particularly where regulatory resources are limited. The process offers a structured basis for identifying products that have undergone dossier review, site evaluation, sample testing, and clinical evidence assessment. This can support access to essential treatments and supply through global health initiatives.